Characterization of Immune Response in Participants from a Posdinemab Study
NOPRODALZ0005
Phase 1 other active
Quick answer
Characterization of Immune Response in Participants from a Posdinemab Study for Early Alzheimer's disease is a Phase 1 program (other) at Janssen-Cilag International N.V. with 1 ClinicalTrials.gov record(s).
Program details
- Company
- Janssen-Cilag International N.V.
- Indication
- Early Alzheimer's disease
- Phase
- Phase 1
- Modality
- other
- Status
- active